- Home
- VTEX vs VSTM Comparison
VTEX vs VSTM Comparison
Compare VTEX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTEX | VSTM |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 710.7M | 723.8M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VTEX | VSTM |
|---|---|---|
| Price | $3.76 | $7.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $6.96 | ★ $13.38 |
| AVG Volume (30 Days) | 752.2K | ★ 1.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.40 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $234,115,000.00 | $13,379,000.00 |
| Revenue This Year | $9.00 | $208.54 |
| Revenue Next Year | $13.06 | $251.40 |
| P/E Ratio | $53.77 | ★ N/A |
| Revenue Growth | 3.65 | ★ 33.79 |
| 52 Week Low | $3.65 | $4.01 |
| 52 Week High | $6.93 | $11.25 |
Technical Indicators
Market Signals| Indicator | VTEX | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 37.70 |
| Support Level | $3.66 | $7.59 |
| Resistance Level | $3.84 | $8.14 |
| Average True Range (ATR) | 0.09 | 0.53 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 33.33 | 11.33 |
Price Performance
Historical ComparisonAbout VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.